Condition: Diffuse Large B Cell Lymphoma (DLBCL) · Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.
This description comes directly from the study's public registry record.
Meiping Kong · +8613735478976 · cxykongmeiping@eastchinapharm.com
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| The Affiliated Tumor Hospital of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| Affiliated Tumor Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| HunanCancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Not Yet Recruiting |
| The First Affiliated Hospital Of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07124936